Company / Capital Returned to Shareholders
ADMA Biologics, Inc. Capital Returned to Shareholders History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$31.9M
FY2025
5-year range
$0 / $31.9M
FY2023-FY2025
Trend
-
vs FY2024
Sector context
#32 of 52
Health Care
What the data says
At $32M, ADMA Biologics, Inc.'s capital returned to shareholders ranks #32 of 52 in the Health Care sector. Improved from $0 to $32M over the past 2 years.
Based on SEC 10-K filings.
$32M in FY2025.
Improved from $0 to $32M over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#32 of 52 in Health CareTop 62% of 52This company $31.9M Sector average $1.3B
▼
-97.6% below sector average
Key checks
Key Insights
- Ranks #32 out of 52 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $31.9M | - |
| FY2024 | $0 | - |
| FY2023 | $0 | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026